Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center.


Journal

Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257

Informations de publication

Date de publication:
2020
Historique:
received: 07 04 2020
revised: 11 08 2020
accepted: 16 09 2020
entrez: 16 10 2020
pubmed: 17 10 2020
medline: 17 10 2020
Statut: epublish

Résumé

Soft tissue tumors are diagnostically challenging, and it is recommended that these are reported or reviewed by specialist soft tissue pathologists. We present our experience with second-opinion (consultation) cases in a specialist tertiary sarcoma center. The aim of this study was to determine areas of diagnostic difficulty in soft tissue pathology. We assessed 581 second-opinion cases which were reviewed by two experienced pathologists in a period of one year. There was 62% concordance between the original and the second-opinion diagnosis, with diagnostic discrepancy in 38%. The largest group of soft tissue neoplasms received for second opinion was fibroblastic/myofibroblastic tumors, and most major diagnostic problems were encountered in adipocytic and so-called "fibrohistiocytic" tumors. Major diagnostic errors impacting management were found in 148 cases (25%). Morphologic assessment of tumors, judicious use of molecular techniques, newer immunostains and their interpretation, along with importance of knowledge of rarer entities were found to be most useful in avoiding errors.

Identifiants

pubmed: 33061792
doi: 10.1155/2020/9810170
pmc: PMC7542501
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9810170

Informations de copyright

Copyright © 2020 Asha Rupani et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Références

PLoS One. 2018 Apr 5;13(4):e0193330
pubmed: 29621244
Int J Surg Pathol. 2016 Dec;24(8):685-691
pubmed: 27363432
Cancer. 1986 Jul 15;58(2):306-9
pubmed: 3719523
Mod Pathol. 2014 Jan;27 Suppl 1:S47-63
pubmed: 24384853
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
Future Oncol. 2017 Jan;13(2):185-194
pubmed: 27600625
J Orthop Sci. 2008 May;13(3):273-82
pubmed: 18528664
Mod Pathol. 2010 Oct;23(10):1301-6
pubmed: 20495536
Sarcoma. 2009;2009:741975
pubmed: 19503800
J Surg Oncol. 2008 Jan 1;97(1):40-3
pubmed: 17918224
Virchows Arch. 2018 Sep;473(3):351-360
pubmed: 29623468
Sarcoma. 2014;2014:686902
pubmed: 25165418
Am J Clin Pathol. 2001 Oct;116(4):473-6
pubmed: 11601130
Genes Chromosomes Cancer. 2019 Feb;58(2):111-123
pubmed: 30382607
Sarcoma. 2015;2015:812089
pubmed: 25810689
Semin Diagn Pathol. 2019 Mar;36(2):85-94
pubmed: 30857767
Int J Surg Pathol. 2016 Feb;24(1):5-15
pubmed: 26399578

Auteurs

Asha Rupani (A)

Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK.

Magnus Hallin (M)

Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK.

Robin L Jones (RL)

Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK.
The Institute of Cancer Research, London SW3 6JB, UK.

Cyril Fisher (C)

The Institute of Cancer Research, London SW3 6JB, UK.
Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Foundation Trust, Robert Aitken Institute for Clinical Research, University of Birmingham, Birmingham B15 2TT, UK.

Khin Thway (K)

Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK.
The Institute of Cancer Research, London SW3 6JB, UK.

Classifications MeSH